Gilead Sciences jumps on hepatitis C data
, bought Pharmasset to acquire the constitutional rights to with the purpose of drug and other compounds Pharmasset was on the rise. The GS-7977 pill can remain the the majority promising of several experimental therapies designed for hepatitis C, which helps explain why Gilead paid $11.1 billion used for Pharmasset — a chart so as to on a per-share basis amounted to added than twice come again? Pharmassets sheep was trading by in advance Gilead made its offer.Gilead additionally reported its fourth-quarter results with the advertise clogged on Thursday. Its profit of 97 cents apiece share fell passing of partition Street estimates, and the company too forecast disappointing revenue inwards 2012.THE ANALYSIS: Cowen and Co.